Investigational drug · Phase 2
OVX836
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Influenza.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
7
Any phase or sponsor naming "OVX836"
First trial start
2025
Sep 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OVX836", any sponsor or status.
Conditions studied
As listed on its trial records.
- Influenza
Approved drugs for the same conditions: Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "OVX836" as an intervention, largest first.
- Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μgPivotal-lookingCompleted
OsivaxIndustry
NCT05569239 · 2,891 participants · Start Sep 8, 2025 · Primary completion May 18, 2026
Drug: OVX836 480µg; Saline Solution · For: Influenza
Sites: Antwerp, Belgium; Ghent, Belgium; Mechelen, Belgium · 16 sites in all
- Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.Pivotal-lookingCompleted
OsivaxIndustry
NCT05734040 · 478 participants · Start May 10, 2023 · Primary completion Aug 10, 2023
Drug: OVX836 480µg; Fluarix Tetra and 2 more · For: Influenza
Sites: Kanwal, Australia; Sydney, Australia; Brisbane, Australia · 9 sites in all
- Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 YearsPivotal-lookingCompleted
OsivaxIndustry
NCT04192500 · 300 participants · Start Dec 11, 2019 · Primary completion Sep 7, 2020
Drug: OVX836; Quadrivalent seasonal influenza vaccine (Influvac TetraTM) · For: Influenza
Sites: Ghent, Belgium
- Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.Pivotal-lookingCompleted
OsivaxIndustry
NCT05060887 · 239 participants · Start Nov 15, 2021 · Primary completion Feb 1, 2022
Drug: OVX836-003; Saline solution · For: Influenza
Sites: Ghent, Belgium
- Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.Pivotal-lookingCompleted
OsivaxIndustry
NCT05284799 · 180 participants · Start May 9, 2022 · Primary completion Jul 19, 2022
Drug: OVX836 480µg; Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra) and 1 more · For: Influenza
Sites: Brookvale, Australia
- Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836Pivotal-lookingCompleted
OsivaxIndustry
NCT06582277 · 117 participants · Start Oct 22, 2024 · Primary completion Jun 2, 2025
Drug: OVX836 shot · For: Vaccine-Preventable Diseases; Influenza
Sites: Ghent, Belgium
OsivaxIndustry
NCT03594890 · 72 participants · Start Jun 12, 2018 · Primary completion Aug 7, 2019
Drug: OVX836 (Intramuscular); Placebo (Intramuscular) and 2 more · For: Influenza
Sites: Antwerp, Belgium
Newest research
PubMed records naming it or its code names, newest first.
- Double-Blind, Randomized, Phase 2a Study to Evaluate the Safety and Immunogenicity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, Co-Administered with Fluarix Tetra® or Afluria Quad®.
Groth N, Bruhwyler J, Piat E, et al. · Vaccines (Basel) 2026
- Safety and Immunogenicity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, Co-Administered with Fluarix® Tetra, a Seasonal Hemagglutinin-Based Vaccine.
Groth N, Bruhwyler J, Tourneur J, et al. · Vaccines (Basel) 2025
- Evaluation of Safety, Immunogenicity and Cross-Reactive Immunity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, in Older Adults.
Jacobs B, Leroux-Roels I, Bruhwyler J, et al. · Vaccines (Basel) 2024
- Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial.
Leroux-Roels I, Willems P, Waerlop G, et al. · Lancet Infect Dis 2023
- Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results.
Withanage K, De Coster I, Cools N, et al. · J Infect Dis 2022
- Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.
Leroux-Roels I, Waerlop G, Tourneur J, et al. · Front Immunol 2022
Also in development for Influenza
- Investigational Influenza VaccinePhase 34 trials
BioNTech SE · Influenza, COVID-19, COVID-19 (Coronavirus Disease 2019)
- GP681Phase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- GP681 SimulantPhase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- BRC-201TG-1000, Pixavir MarboxilPhase 31 trial
Boryung Biopharma Co., Ltd. · Influenza
- mRNA-1018-H5Phase 31 trial
Moderna · Influenza
- Fluzone QudrivalentPhase 22 trials
Sanofi · Healthy Volunteers, Influenza Immunization, Influenza
- TRX-100Phase 22 trials
Traws Pharma, Inc. · Influenza
- ApomivirFE-L-APO, drug substancePhase 21 trial
Far East Bio-Tec Co., Ltd · Influenza
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.